A Phase II, Multicenter Trial Aiming to Evaluate the Clinical Interest of a Monotherapy With BKM120 , a Phosphoinositide 3-kinase (PI3K) Inhibitor in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive Under Platin and Cetuximab-based Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 25 Oct 2019
Price : $35 *
At a glance
- Drugs Buparlisib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms PIK-ORL
- 20 Jun 2019 Status changed from recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 09 Jul 2018 Planned End Date changed from 1 Jan 2019 to 1 Apr 2020.